Search

Your search keyword '"Atmar, Robert L"' showing total 1,037 results

Search Constraints

Start Over You searched for: Author "Atmar, Robert L" Remove constraint Author: "Atmar, Robert L"
1,037 results on '"Atmar, Robert L"'

Search Results

1. Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case.

2. Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial

3. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.

4. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

6. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants

8. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

10. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial

11. Risk of COVID-19 after natural infection or vaccination

12. Remdesivir for the Treatment of Covid-19 — Final Report

13. Use of Human Intestinal Enteroids to Evaluate Persistence of Infectious Human Norovirus in Seawater

19. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

21. Glycan recognition in globally dominant human rotaviruses.

23. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial

24. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults

30. Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody

31. A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies.

32. Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum

36. Risk of COVID-19 after natural infection or vaccination

38. Hurricane-Associated Mold Exposures Among Patients at Risk for Invasive Mold Infections After Hurricane Harvey — Houston, Texas, 2017

40. Determining a urinary-specific antibiogram and risk factors of trimethoprim/sulfamethoxazole, ciprofloxacin and multidrug resistance among Enterobacterales in primary care.

41. Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

46. Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

48. INTRA- AND INTER-HOST EVOLUTION OF HUMAN NOROVIRUS IN HEALTHY ADULTS

49. Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive COVID-19 Treatment Trial (ACTT) as a Test Case

Catalog

Books, media, physical & digital resources